NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Health · USD · ETF

iShares Biotechnology ETF (IBB) ETF Analysis

IBB
Expense ratio 0.44% Yield 0.16% Assets $11.20B Since February 5, 2001 Family iShares

Last Updated: October 21, 2026

$211.55
+$1.05 (+0.50%)

October 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IBB with… →

IBB Annualized Returns

PeriodAnnualized$100 becomes
1 year+35.86%$135.86
3 years+22.06%$181.85
5 years+6.16%$134.82
10 years+9.29%$243.13

Returns are total returns computed from daily closes, with dividends reinvested. As of October 21, 2026.

IBB Return by Calendar Year

2016 and 2026 are partial years

View as table ↓View as chart ↑
YearReturn
2026 (partial year)+25.46%
2025+27.98%
2024−2.41%
2023+3.76%
2022−13.69%
2021+0.95%
2020+26.01%
2019+25.42%
2018−9.53%
2017+21.08%
2016 (partial year)−9.73%

IBB Monthly Returns

−15%+16%
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+2.2+1.7−3.6−0.1+2.1+10.5−2.0+12.1+0.7+0.5——
2025+4.9−1.2−6.6−1.0−3.8+3.9+4.9+4.1+4.5+10.4+9.1−2.8
2024−1.1+1.8+0.4−7.5+5.5+2.5+7.8+0.1−1.6−3.6+0.9−6.6
2023+4.0−6.9+1.6+1.0−3.2+0.5+1.9−0.5−4.9−7.0+6.4+12.4
2022−13.6−4.4+3.5−10.5+0.0+0.8+5.5−2.1−3.6+9.9+6.2−3.8
2021+6.0−2.3−4.0+2.7−1.7+7.7+1.3+3.9−6.1−1.3−3.4−1.0
2020−5.6+0.1−5.3+15.1+8.7+1.5−1.7+0.9−0.1−3.5+11.0+4.5
2019+13.8+2.8−0.7−4.8−6.1+9.2−3.2−2.6−3.3+7.9+11.5+0.8
2018+6.8−5.3−1.2−2.9+4.6+1.4+6.1+4.9−0.2−14.7+4.8−11.6
2017+4.8+6.9−1.2+1.5−4.0+8.6+2.9+4.5+0.1−5.8+0.5+1.6

Monthly total returns with dividends reinvested; each cell prints its signed value.

IBB Volatility & Risk

Volatility: 10 yrs · Beta: 3 yrs
Annualized volatility
23.24%
Beta (3y)
0.70
Best year
+27.98%

2025

Worst year
−13.69%

2022

Volatility is the annualized standard deviation of daily returns. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Top Holdings

# Symbol Name Weight
1 GILD Gilead Sciences Inc 8.08%
2 AMGN Amgen Inc 7.78%
3 VRTX Vertex Pharmaceuticals Inc 7.62%
4 REGN Regeneron Pharmaceuticals Inc 5.28%
5 MRNA Moderna Inc 4.94%
6 NTRA Natera Inc 3.91%
7 ARGX argenx SE ADR 3.74%
8 ILMN Illumina Inc 2.89%
9 RVMD Revolution Medicines Inc Ordinary Shares 2.78%
10 BIIB Biogen Inc 2.33%

Analysis

Data-derived

Fund Overview

iShares Biotechnology ETF (IBB) is an exchange-traded fund in the Health category. The fund is issued by iShares. It has been trading since February 5, 2001. Total net assets stand at $11.20B. Annual costs run at an expense ratio of 0.44%. On a $10,000 position that is $44.00 a year.

The largest positions on file are Gilead Sciences Inc (GILD), Amgen Inc (AMGN), and Vertex Pharmaceuticals Inc (VRTX). Gilead Sciences Inc alone accounts for 8.08% of the portfolio. The ten largest positions together make up 49.34% of the fund.

Performance Analysis

The most recent close on file for IBB is $211.55, dated October 21, 2026. Over the trailing twelve months the total return is +35.86%. Across 10 years the annualized return works out at +9.29%. The trailing distribution yield is 0.16%.

Across the complete calendar years on file, 2025 returned +27.98% and 2022 returned −13.69%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is +25.46% year to date.

Price & Risk Profile

The 52-week range on file runs from $153.25 to $217.12. The latest close sits 38.04% above that 52-week low. Annualized volatility over the trailing 10 years is 23.24%. Beta against the wider market is reported at 0.7. The volatility figure is calculated from the stored daily closes, the same series the charts on this page use.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Health ETFs

XLV

State Street Health Care Select Sector SPDR ETF

$43.39B

 VHT

Vanguard Health Care Index Fund ETF Shares

$21.81B

 XBI

State Street SPDR S&P Biotech ETF

$10.36B

 ARKG

ARK Genomic Revolution ETF

$2.22B
View all Health ETFs →